secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001628280-25-022759
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Bioworks Q1 revenue up 27% to $48M, guided revenue raised; net loss narrows to $91M
--------------------------------------------------------------------------------

- Q1 2025 total revenue $48M (+27% YoY); core revenue ex-deferred release $41M (+8%). GAAP net loss $(91)M vs $(166)M prior year.
- Adjusted EBITDA $(47)M improved from $(117)M; cash & equivalents $517M.
- Raises FY2025 total revenue guidance to $167-187M (from $160-180M); Cell Eng. guidance $117-137M.
- Cost reduction target: $250M annualized by Q3 2025; achieved $205M run-rate in Q1.
- Awarded $29M ARPA-H contract for distributed manufacturing using wheat germ cell-free systems.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828025022759/0001628280-25-022759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828025022759/dna-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-022759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer